Publication Year

Cyr P, Sidhu M, Hussain R, Hromin T, Jensen I, Kuan R. Dual-acting osmotic and stimulant laxative for bowel cleansing in an elderly population: A US payer budget impact analysis. Abstract PCN22, ISPOR 18th Annual International Meeting, 2013.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406; doi: 10.1002/jat.2799.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Reddick H. Air quality along the Texas Gulf Coast. Poster, Society of Toxicology 52^nd Annual Meeting, San Antonio, TX, 2013.

Belova A, Narayan T, Brown L, Haskell J, Bozeman S, Lamb J. A framework to assess aflatoxin public health impacts in developing countries with application to Nigeria and Tanzania. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Brown L, Lynch M, Post E, Belova A. Determine a concentration response relationship suitable for estimating adult benefits of reduced lead exposure. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Karchapati L, Bednar KJ, Adams DE, Wu Y, Mitter RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. 2013. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 47:94–103.

Shah F, Greene N. 2013. Analysis of Pfizer compounds in EPA’s ToxCast chemicals-assay space. Chem Res Toxicol 27(1):86-98; doi: 10.1021/tx400343t. PMID: 24328225.

Naven RT, Swiss R, Klug-McLeod J, Will Y, Greene N. 2013. The development of structure-activity relationships for mitochondrial dysfunction: Uncoupling of oxidative phosphorylation. Toxicol Sci 131(1):271-278; doi: 10.1093/toxsci/kfs279. PMID: 22977170.

Sterner TR, Ruark CD, Covington TR, Yu KO, Gearhart JM. 2013. A physiologically based pharmacokinetic model for theoxime TMB-4: Simulation of rodent and human data. Arch Toxicol 87:661–680; doi: 10.1007/s00204-012-0987-z.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY. 2013. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol 271(3):299–308; doi: 10.1016/j.taap.2011.01.017.